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Buruli or Bairnsdale Ulcer (BU) is a
neglected infectious disease caused by
Mycobacterium ulcerans and is characterized
by necrotic cutaneous lesions. Infection is
challenging to treat, and the ideal combi-
nation of surgery and antimicrobial ther-
apy continues to evolve. M. ulcerans has
been endemic to the Bellarine peninsula in
Victoria, Australia, since 1998, with more
than 250 cases of infection. Studies have
illustrated the safety and efficacy of
antimicrobial therapy [1–5], and our
standard treatment practice has evolved
over the last 15 years to comprise limited
surgical debridement with combination
antimicrobial therapy.
Immune reconstitution inflammatory
syndrome (IRIS) is a paradoxical reaction
occurring during treatment of an infection,
recognized clinically by deterioration after
initial improvement. These reactions are
well described in tuberculosis and leprosy,
where effective antimicrobial killing may
be accompanied by (transient) clinical
deterioration during treatment [6,7], pre-
dominantly in HIV-infected patients after
the introduction of antiretroviral therapy
[8]. IRIS reactions may also occur in
patients with a competent immune system
[9]. Our group and others have described
paradoxical reactions occurring during the
treatment of M. ulcerans infection with
antimicrobials [10,11].
In cases of Mycobacterium tuberculosis (TB)
infection complicated by IRIS, steroid
therapy is recommended. A randomized
placebo-controlled trial of IRIS in TB
found that prednisone reduced the need
for hospitalization and therapeutic proce-
dures and hastened improvements in
symptoms, performance, and quality of
life [12]. In our group’s description of
paradoxical reactions during therapy for
BU, we proposed that adjunctive cortico-
steroid therapy may improve healing and
prevent the need for further surgical
intervention [10]. In the last 2 years our
group has therefore acquired an early
experience with the use of steroid therapy
to treat severe IRIS in patients with M.
ulcerans infection.
From 1998 through the end of 2011,
our group has treated 163 patients with M.
ulcerans infection with antimicrobials. We
have assessed both retrospectively (until
2009) and prospectively (since 2009) that
31 patients (19%) developed paradoxical
reactions. To date, five patients have been
treated with steroid therapy for severe
paradoxical reactions.
The patients treated with corticosteroids
were aged between 9 and 84 years. All
patients were ambulatory and managed as
outpatients. These patients developed
IRIS 2–13 weeks after commencing com-
bination antimicrobial therapy after expe-
riencing an initial clinical improvement in
the erythema and induration surrounding
the lesion. The clinical findings that were
indicative of a severe paradoxical reaction
included markedly increased inflammation
and induration surrounding the M. ulcerans
lesion, copious wound discharge, the
appearance of new secondary lesions,
and necrotic eschar formation (see
Table 1).
Clinical deterioration during antibiotic
treatment may be interpreted as treatment
failure, leading to further potentially
disfiguring and unnecessary surgery and
either a change or prolongation of antimi-
crobial therapy [10]. Therefore, we be-
lieve that confirmation of a paradoxical
reaction via histopathological assessment
of a biopsy specimen and mycobacterial
cultures are important in the therapeutic
decision-making process for patients with
clinical deterioration during antimicrobial
therapy for M. ulcerans. Histopathological
findings of a paradoxical reaction include
ulceration and necrosis, a florid mixed
inflammatory infiltrate with multinucleat-
ed giant cells, usually sparse or absent acid
fast bacilli (AFB), and negative mycobac-
terial cultures (see Figures 1 and 2)
[10,13], although excised tissue may
remain positive for M. ulcerans via poly-
merase chain reaction. In all of our cases
with a paradoxical reaction, mycobacterial
cultures were negative regardless of wheth-
er AFBs were seen on microscopy. We
recognize that biopsy and histopathology
may not be readily available in resource-
limited settings managing patients with
BU. In these cases, a diagnosis of para-
doxical reaction based on clinical param-
eters will be most appropriate.
In our patients a provisional diagnosis of
severe IRIS was followed by commence-
ment of prednisone at a dose of 0.5–1 mg/
kg daily with the aim of reducing further
tissue destruction, preserving skin grafts,
and limiting the extent of further surgery.
In all patients with M. ulcerans treated with
steroid therapy, there was a marked
clinical improvement in the appearance
of the lesion within days to weeks, and the
duration of prednisone therapy used was
4–6 weeks, with gradual tapering of the
dose after the first 2–3 weeks of therapy.
All patients tolerated prednisone well with
no side-effects, and antimicrobial therapy
was not changed nor prolonged beyond 12
weeks despite the occurrence of a paradox-
ical reaction. All patients underwent de-
bridement of their M. ulcerans lesions before
or after the commencement of the predni-
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sone. Ultimately all have achieved complete
healing without recurrence between 9–21
months after initial treatment.
M. ulcerans produces a necrotizing mac-
rolide toxin, mycolactone, which pro-
foundly suppresses elements of innate
and adaptive cell-mediated immunity,
thereby enhancing progression of BU
[14]. Histopathologically, BU lesions are
characterized by a poor inflammatory
response. In some BU lesions, treatment
with antibiotics may cause temporary
immune-mediated inflammation with clin-
ical worsening, which we and others have
proposed as a paradoxical sign of treat-
ment success [10,11].
In the cases that we have treated with
prednisone for a paradoxical reaction
during therapy for M. ulcerans infection,
subsequent severe clinical deterioration
has occurred after initial improvement on
antibiotic therapy. This may be explained
by an apparent reversal of the local
immune-tolerant state of active M. ulcerans
infection due to antibiotic therapy. A local
cellular immune response has been shown
to develop in these situations as produc-
tion of mycolactone is reduced [14],
presumably in response to persisting
mycobacterial antigens. We believe that
in our patients, the current practice of
limited surgical debridement with combi-
nation antimicrobial therapy results in
incomplete excision of mycobacteria-in-
fected tissue, which may potentiate the
development of paradoxical reactions.
As with paradoxical immune reac-
tions to antimicrobial therapy for other
mycobacterial diseases where corticoste-
roids are known to be effective [12,15],
our approach with these BU infections
was to commence prednisone as adjunc-
tive treatment to antibiotics to settle the
severe immune-mediated reaction and
limit secondary tissue damage. The dose
Figure 1. Skin biopsy from patient A after diagnosis of BU. Skin biopsy (62.5
magnification) showing ulceration and extensive undermining necrosis of the dermis and
subcutaneous fat with minimal inflammation, typical of B.U. Insert, Wade Fite stain (640
magnification) showing numerous acid fast bacilli.
doi:10.1371/journal.pntd.0001767.g001
Table 1. Clinical details of patients with paradoxical reactions treated with corticosteroids.
Age Gender Lesion Location
Time to Paradoxical
Reaction (Days)
Initial Size
of Lesion
Features of
Paradoxical Reaction
Features after
Steroid Therapy
62 F Achilles region, ulcer 21 265 cm ulcer;
induration 1364 cm
Increased wound discharge
and pain
Ulcer unchanged;
discharge and pain resolved
83 F Posterior heel, ulcer 92 363 cm ulcer;
induration 568 cm
864 cm induration and
wound ooze
262 cm lesion; no induration
9 F Lower leg, ulcer 53 1 cm ulcer;
minimal induration
Marked induration and
wound discharge
Ulcer unchanged; swelling
and
discharge resolved
14 F Knee, ulcer 17 8 mm ulcer;
induration 262 cm
Induration 666 cm and
wound discharge
Ulcer unchanged; induration
and discharge resolved
84 M Elbow, edematous lesion 30 No ulcer;
induration 13611 cm
Induration 28620 cm Induration resolved
Time to paradoxical reaction was defined as the number of days from the commencement of antibiotics until the onset of the paradoxical reaction.
doi:10.1371/journal.pntd.0001767.t001
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was chosen based on recommendations
for the treatment of TB-IRIS reactions
[12]. The use of prednisone in these BU
cases was associated with a settling of
the skin lesions and ultimately prevented
the need for further extensive surgery.
Furthermore, complete healing oc-
curred despite not extending the dura-
tion of antimicrobial therapy beyond 12
weeks.
We acknowledge several factors that
may limit the use of steroid therapy in this
clinical setting. Prednisone may adversely
affect outcomes by suppressing the host
immune response to M. Ulcerans, and
reduced serum levels of prednisone may
result from an interaction with rifampin
[16,17]. In addition, the use of steroid
therapy is associated with many potential
complications, and therefore, not all
patients with BU may be optimal candi-
dates for steroid therapy. For example, in
BU endemic areas with high rates of co-
existent infections such as tuberculosis or
strongyloidiasis, prednisone may adversely
affect the outcomes of these co-infections
[18]. It is advisable during therapy with
corticosteroids that the following parame-
ters be monitored: mood changes, sleep
disturbance, and increase in appetite.
Blood glucose levels and blood pressure
should be monitored where there is a
history of diabetes mellitus or hypertension
or a clinical predisposition to either of
these conditions.
There are potential limitations to our
purely observational description of success
with the use of adjunctive steroid therapy
in patients with a severe paradoxical
reaction during antimicrobial treatment
for BU. For instance, in the absence of a
control group, it is unclear what the
progress of the healing of these skin lesions
would have been without steroid therapy,
and whether the outcome may have been
the same. Furthermore, the use of limited
debridement of lesions in conjunction with
antimicrobials, both of which are known
to be effective in the cure of M. ulcerans
infection [1–3], may have influenced
healing significantly such that the effect
of steroids alone is unclear. Nonetheless,
there is historical precedence that is
supportive of corticosteroid use in para-
doxical reactions with other mycobacterial
infections [12].
To our knowledge this is the first
description of corticosteroid use in cases
of M. ulcerans where severe paradoxical
reactions to antibiotic treatment have
occurred. In our early experience, the
use of prednisone at a dose of 0.5–1 mg/
kg was clinically effective and well tolerat-
ed. Moreover, the use of steroid therapy in
addition to antimicrobial therapy in our
patients was associated with good cosmetic
outcomes, no significant adverse effects,
and no need for further major surgical
intervention. Hence we would advocate
for further prospective study of corticoste-
roid use in the treatment of M. ulcerans–
associated severe paradoxical reactions.
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Figure 2. Skin biopsy from patient A with IRIS 7 weeks through antibiotic treatment
for BU. Skin biopsy (610 magnification) showing mixed inflammatory and granulation tissue
reactionwith prominentmultinucleated giant cells, typical of a paradoxical reaction during antibiotic
therapy for BU. Insert, Wade Fite stain (640 magnification) showing very sparse acid fast bacilli.
doi:10.1371/journal.pntd.0001767.g002
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